News

Hims & Hers Stock Drops More Than 30% After Novo Nordisk Breakup
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...
Novo Nordisk ends collaboration with Hims & Hers
Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...
Monthly weight loss drug helps people lose 20% of body weight, trial finds
A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...
Novo Nordisk
Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing" Novo Nordisk said it will stop selling Wegovy on ...
Devdiscourse1h
Pharmaceutical Rift: Novo Nordisk and Hims & Hers Clash Over Weight-Loss Drug
Novo Nordisk ended its agreement with Hims & Hers for the sale of Wegovy after disagreements over marketing tactics and ...
Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints
Novo Nordisk's U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.
Why Novo Nordisk Stock Is Sinking Today
Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug. Patients ...
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investors Concern
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...
PharmExec1h
Novo Nordisk’s CagriSema Falls Short of 25% Weight Loss Target in Patients with Obesity or Overweight
Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...